

## EORTC NEWS AND REPORTS

These reports will appear on a monthly schedule whenever available. They are based on information provided by individuals or clinical and research groups pertinent to cancer research. More detailed information if needed may be obtained by writing to

H.J. Tagnon, M.D.  
Institut Jules Bordet  
Boulevard de Waterloo, 125  
1000 Brussels (Belgium)  
Tel : (2)538.27.66 - Fax : (2)539.41.66

---

### Guidelines for the preparation for publication of reports from EORTC Cooperative Groups

1. The chairman, convener or secretary of the Group is requested to mail the report to the office of the European Journal of Cancer & Clinical Oncology. The reports will be edited and published in the Journal within 6 to 8 weeks after reception in the office.

Address : H.J. Tagnon, M.D.

Editor, EUROPEAN JOURNAL OF  
CANCER & CLINICAL ONCOLOGY  
Institut Jules Bordet  
Rue Héger-Bordet, 1  
1000 Brussels (Belgium)


2. Please send the report typewritten on one side of page, double spaced with a 5 cm left margin. Brevity is essential. Tables and figures are difficult to print and should be replaced by an appropriate text.
3. Please consult the reports published in the March 1989 issue of the Journal and consider them as models to be adopted for all reports with possible exceptional adaptations.
4. We request omission of list of names of attendants to the group meetings. Reports should be signed by either the chairman, convener, secretary of the group, or by all three ad libitum.
5. Please add as a conclusion to your report : "Additional information may be obtained by writing to the secretary of the group".

6. Protocols will be published at the request of the groups.

This office will be glad to receive your comments, criticism and suggestions on the edition and publication of your reports.

The Editor.

## E.O.R.T.C. - ORGANIGRAM



**EORTC INFORMATION ON :****1. Policy :**

EORTC Foundation President <b>R. Grierson</b> 14th Floor Bowater House 68, Knightsbridge London SW1X 7LT U.K. Tel 44-1-581.90.99 Fax 44-1-581.90.49 EuroCode : -	EORTC President <b>L. Denis</b> Dept of Urology A.Z. Middelheim Antwerp 2020 Belgium Tel 32-3-280.36.02 Fax 32-3-218.46.96 EuroCode : DENIS	EORTC Vice-President <b>M. Tubiana</b> Institut Gustave-Roussy 39, rue C. Desmoulins 94805 Villejuif Cedex France Tel 33-1-45.59.49.09 Fax 33-1-47.26.92.74 EuroCode : TUBIANA	EORTC Secretary-General <b>A. Costa</b> European School of Oncology via Venezian 1 20133 Milan Italy Tel 39-2-236.42.79 Fax 39-2-266.46.62 EuroCode : COSTA	EORTC Treasurer <b>F. Cleton</b> University Hospital P.O. Box 9600 2300 RC Leiden The Netherlands Tel 31-71-26.34.64 Fax 31-71-22.70.90 EuroCode : CLETON
---	--	---	--	--

**2. Function & Journal & EORTC Newsletter :**

Executive Director <b>H. Tagnon</b> EORTC Institute Boulevard de Waterloo 125 1000 Brussels Belgium Tel 32-2-538.27.66 (or 32-2-535.34.80) Fax 32-2-539.41.66 EuroCode : -	Executive Secretary <b>A.M. Stift</b>
--	--

**3. Data Center :**

Director <b>M. Staquet</b> EORTC Data Center Boulevard de Waterloo 125 1000 Brussels Belgium Tel 32-2-539.28.05 Fax 32-2-539.03.74 EuroCode : STAQUET	Director <b>H. Pinedo</b> EORTC New Drug Development Office Free University Hospital De Boelelaan 1117 1081 HV Amsterdam, The Netherlands Tel 31-20-548.51.92 Fax 31-20-548.63.89 (or 31-20-548.48.98) EuroCode : PINEDO
---	--

**4. New Drugs :**

Director <b>H. Pinedo</b> EORTC New Drug Development Office Free University Hospital De Boelelaan 1117 1081 HV Amsterdam, The Netherlands Tel 31-20-548.51.92 Fax 31-20-548.63.89 (or 31-20-548.48.98) EuroCode : PINEDO	Executive Secretary <b>Mrs A. Money-Coutts</b> EORTC Foundation 132-135 Long Acre London WC2E 9AH U.K. Tel 44-1-379.35.05 Fax 44-1-836.68.39 EuroCode : -
--	---

**5. Funding to EORTC :**

Executive Secretary <b>Mrs A. Money-Coutts</b> EORTC Foundation 132-135 Long Acre London WC2E 9AH U.K. Tel 44-1-379.35.05 Fax 44-1-836.68.39 EuroCode : -	Executive Secretary <b>Mrs A. Money-Coutts</b> EORTC Foundation 132-135 Long Acre London WC2E 9AH U.K. Tel 44-1-379.35.05 Fax 44-1-836.68.39 EuroCode : -
---	---

## LETTER FROM THE U.S.

The Clinical Cancer Letter, published in Reston, Virginia, is a supplement to the "Cancer Letter", a weekly letter reporting news of interest to oncologists. This supplement will publish European news from EORTC, among which a coverage of clinical groups and cancer trials. The first such coverage of EORTC Cooperative Groups appeared in the volume 12, no 7, 1989, pages 7-8 of the Clinical Cancer Letter. This coverage includes the address of the Central Office in Brussels as well as the names of the chairmen and the title of the cooperative studies. Jerry D. Boyd, editor of both Letters expresses the wish to make European news an important feature of the new supplement. Inquiries and communications can be addressed to him or to the office of EORTC.

"The Cancer Letter"  
Editor: Jerry D. Boyd  
P.O. Box 2376  
Reston, VA 22090  
U.S.A.  
Phone: (703) 620-4646

## REPORT-EORTC LUNG CANCER WORKING PARTY MEETING

Brussels, June 24, 1989

**Participants:** Awada (Bruxelles), Body (Bruxelles), Brohée (Montignies-le-Tilleul), Bureau (Reims), Dabouis (Nantes), Diana (Bruxelles), Donnadiou (Nantes), Efreidis (Athènes), Fiche (Nantes), Finet (Braine-l'Alleud), Klastersky (Bruxelles), Lacroix (Nantes), Lecomte (Charleroi), Libert (Boussu), Longeval (Baudour), Mommen (Bruxelles), Moury (Boussu), Paccagnella (Padoue), Paesmans (Bruxelles), Quarré (Charleroi), Ravoet (Bruxelles), Richard (Charleroi), Richez (Boussu), Rocmans (Bruxelles), Schmerber (Bruxelles), Sculier (Bruxelles), Tagnon (Tournai), T'Hooft (Boussu), Thiriaux (Charleroi), Thirion (Bruxelles), Van Cutsem (Namur), Vandermoten (Bruxelles), Wackenier (Mons).

## 1. REVIEW OF ONGOING STUDIES

A. SCLC (EORTC 07871): phase III randomized study comparing an intensive multiple drug chemotherapy versus standard combination:

143 patients have been registered so far  
2 are ineligible and 10 inevaluable  
66 have been evaluated

B. Biomarkers in lung cancer (EORTC 07851):

On 146 patients with SCLC and serum sample before treatment, 53% have a serum sample at first evaluation.  
On 164 patients with NSCLC and serum sample before treatment, 40% have a serum sample at first evaluation.

## 2. PILOT STUDIES

A. NSCLC: Phase II study of cisplatin + vindesine + 5-fluorouracil + mitomycin C in advanced disease:  
101 patients have been registered and 37 have been evaluated.

B. Ifosfamide + ACNU as salvage therapy for patients with SCLC and failing in protocol 07871:

7 patients have been so far registered: 5 patients in the multiple drugs arm and 2 in the AVE arm.

## 3. 1989 ANNUAL MEETING OF ASCO-AACR

Sculier reported an overview of the studies presented in San Francisco. Most interesting data were reported about weekly chemotherapy and G/GM-CSF supportive therapy in SCLC.

## 4. THIRD WORKSHOP ON SCLC OF THE IASLC HELD IN ELSINORE (DENMARK) IN JUNE 1989

Sculier, Klastersky and Van Houtte have attended this important meeting. An overview of six consensus reports (staging and prognostic factors; CNS; chemotherapy; radiotherapy; BRMS; supportive care) was given by Sculier.

## 5. BIOMARKERS

Body gave a preliminary report about PDN-21 as promising new serum marker for SCLC and NSCLC.

## 6. NEW STUDIES

A. Protoadjuvant chemotherapy in inoperable non metastatic NSCLC: a Phase III comparing 6 courses of MIP (mitomycin C + ifosfamide + cisplatin) to 3 courses of MIP following by radical chest irradiation (60 Gy) was refused by the Protocol Review Committee, mainly because the feeling of the PRC was that chest irradiation had to be included in both arms. The Group disagreed with this conservative argument. Our representatives will go to the next meeting of the PRC to discuss this point. Vandermoten proposed to include into the trial a study about the functional criteria for surgery and irradiation. A protocol will be written by Vandermoten, Bureau, Libert and Thiriaux.

B. New SCLC protocol: a pilot study on standard intensive chemotherapy administered on short intercourse intervals with GM-CSF support will be starting end 1989 at the Institut Jules Bordet.

C. Trials in metastatic NSCLC: a new combination with carboplatin will be designed.

## 7. DATA MANAGING

The group asked for computerisation of the data that are today collected on paper. An interactive program will be designed.

## 8. NEXT PLENARY SESSION

The next plenary session is schedule in Brussels for October 21th, 1989.

## REPORT-EORTC CUTANEOUS LYMPHOMA PROJECT GROUP X. GENERAL MEETING

Gent, Belgium, May 5-7, 1989

At the beginning of May the EORTC Cutaneous Lymphoma Project Group met in Gent/Belgium to continue several projects started in the preceding meeting.

On the first day of the meeting, Friday afternoon, there was a variety of formal presentations which covered clinical, morphological, immunophenotypical and genotypic investigations on cutaneous malignant lymphomas.

On Saturday, the 90 participants were divided into two groups. Those who were not experienced in dermatohistology had the opportunity to go through a series of slides from different pseudolymphomas and lymphomas provided by senior members of the group.

The second group discussed the results of a blind evaluation of proven cutaneous T cell lymphomas. It was remarkable that in some of the forty cases evaluated, all expert agreed, while in other cases there was a considerable variability not only concerning the assignment to a certain cytological subtype but also the decision whether a given case was of low or high grade malignancy. These results are of importance, as controversial cases have then been analyzed again in Gent. We tried to find out why the group failed to come to a consensus diagnosis.

This discussion will lead to the formulation of criteria enabling the dermatohistologist to classify such difficult cases. For example there was no unanimity on how to classify a case which only contained small clusters of a large cell population. During the next meetings, histological criteria will be elaborated concerning such problems.

Another frequent problem in cutaneous malignant lymphomas is the early diagnosis of cutaneous T cell lymphomas, namely mycosis fungoides and its precursors. As the skin provides a unique chance for early detection and treatment of malignant lymphomas, the dermatohistologist get biopsies from initial lesions which are difficult to diagnose due to the minimal disease yet present. Therefore the group analyzed twenty cases of early mycosis fungoides using a panel of more than 50 different criteria which were evaluated the next day by the whole group. A selected group of members of the Project group will meet in the end of June to go through the same cases using the revised criteria and to verify their sensitivity and reliability.

On Saturday afternoon clinical problems of cutaneous malignant lymphomas were discussed. The definition of new cytological entities like pleomorphic T cell lymphomas or large cell anaplastic lymphoma cause a clinical confusion since most cases of pleomorphic T cell lymphomas have been grouped as mycosis fungoides in the past. It remains to be worked out whether these newly defined cytological entities (which were primarily described as lymph node lymphomas) present a different clinical picture and a distinct clinical course. Only if this holds true will it be justified to use these cytological classification also for the skin. Moreover, there was agreement among the participants, that the TNM-classification of the American Mycosis Fungoides Study Group might not be selective enough for important clinical signs, like small dermal papules in mycosis fungoides, which generally indicate a more aggressive disease. Proposals will be elaborated for a more detailed clinical classification.

Finally, members were asked to think about their part in publication of the many data accumulated by the project group. Participants were asked to give written suggestions for possible publications to the secretary and the chairman of the Project group.

The next general meeting of the EORTC Cutaneous Lymphoma Project Group will be held on June 1-3, 1990 in Aarhus/Denmark.

---

#### EORTC BOARD AND COUNCIL

In accordance with a decision of the Board and Council of EORTC a feasibility study group was organized for cancer nurses. The members of this Group are:

Jenny Whelan, Edinburgh, United Kingdom  
Rita Bodenmüller, Essen, FRG  
Célestina Arrigo, Brussels, Belgium  
Yvonne Willems, Bellinzona, Switzerland  
Helen Gall, Amsterdam, The Netherlands  
Clementine Molin-Kuin, Stockholm, Sweden

During the initial period this Study Group will function within the Education Branch of EORTC.

#### NEW DEVELOPMENTS IN THE UNDERSTANDING AND TREATMENT OF SCHIZOPHRENIA

London, England, December 6, 1989

#### NEW PHARMACOLOGICAL APPROACHES TO DEPRESSION AND ANXIETY

London, England, December 7-8, 1989

#### DRUGS AFFECTING CALCIUM IONS THEIR ROLE IN MODERN MEDICINE

London, England, December 13-14, 1989

Information:  
Renata Duke  
IBC Technical Services Ltd.  
Bath House (3rd Floor)  
56, Holborn Viaduct  
London EC1A 2EX  
England, U.K.  
tel: 01-236 4080  
fax: 01-489 0849  
telex: 888870 IBC G

---

#### SIXTH INTERNATIONAL CONFERENCE ON THE ADJUVANT THERAPY OF CANCER

Tucson, Arizona, U.S.A., March 7-10, 1990

Information:  
Mary Humphrey  
Conference Coordinator  
Arizona Cancer Center  
University of Arizona College of Medicine  
Tucson, AZ 85724  
U.S.A.  
tel: (602) 626-2276  
fax: (602) 626-2284

---

#### FIFTH INTERNATIONAL CONFERENCE ON MONO-CLONAL ANTIBODY IMMUNOCONJUGATES FOR CANCER

San Diego, California, U.S.A., March 15-17, 1990

Information:  
Cass Jones  
Professional Conference Management Inc.  
7916 Convoy Court  
San Diego, CA 92111  
U.S.A.  
tel: (619) 565-9921

---

#### EUROPEAN ASSOCIATION FOR CANCER EDUCATION

Bordeaux, France, April 26-28, 1990

Information:  
Dr. B. Hoerni or Dr. A. Ravaud  
Fondation Bergonié  
180 rue de Saint Génès  
33076 Bordeaux, France

or

Dr. W. Bender EdD  
Secretary EACE  
Groningen Faculty of Medicine, BOOG  
Bloemsingel 1,  
9713 BZ Groningen,  
The Netherlands  
tel: (50) 632 888  
fax: (50) 638 883

---

**XIII INTERNATIONAL SYMPOSIUM ON CLINICAL  
HYPERTHERMIA**

Acre, Israel, May 21-25, 1990

Information:

Dr. A. Yerushalmi  
Department of Cell Biology  
The Weizmann Institute of Science  
Rehovot 76100, Israel  
fax: 972-8-466-966

---

**16th LH GRAY MEMORIAL CONFERENCE  
VASCULATURE AS A TARGET FOR  
ANTI-CANCER THERAPY**

Manchester, U.K., September 17-21, 1990

Information:

Dr. J.V. Moore  
Paterson Institute for Cancer Research  
Christie Hospital and Holt Radium Institute  
Wilmslow Road, Manchester M20 9BX  
England, U.K.  
tel: (061) 445-8123 extension 518

---

**INTERNATIONAL SYMPOSIUM ON ADVANCES IN  
NEURO-ONCOLOGY**

San Remo, Italy, September 26-29, 1990

Information:

Fondazione Giovanni Lorenzini  
Via Monte Napoleone, 23  
20121 Milano, Italy  
tel: (02) 76.00.22.67 / 78.38.68  
fax: (02) 781511

---

**FIFTH WORLD CONGRESS ON GESTATIONAL  
TROPHOBLASTIC DISEASE**

London, U.K., October 3-5, 1990

Information:

Dr. Jennifer J. Gallai-Hatchard  
Cancer Research Campaign Laboratories  
Department of Medical Oncology  
Charing Cross Hospital  
Fulham Palace Road  
London, W6 8RF  
U.K.

---

**SIXTH INTERNATIONAL CONFERENCE ON  
MONOCLONAL ANTIBODY IMMUNOCONJUGATES  
FOR CANCER**

San Diego, Arizona, U.S.A., February 28-March 2,  
1991

Information:

Cass Jones  
Professional Conference Management Inc.  
7916 Convoy Court  
San Diego, CA 92111  
U.S.A.  
tel: (619) 656-9921

---